Citation Report
List of articles citing

Clinical approval success rates for investigational cancer drugs

DOI: 10.1038/clpt.2013.117
Clinical Pharmacology and Therapeutics, 2013, 94, 329-35.

Source: https://exaly.com/paper-pdf/54906891/citation-report.pdf
Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
153	Reinventing bioinnovation. *Clinical Pharmacology and Therapeutics*, **2013**, 94, 279-83	6.1	3
152	Evaluation of tumor size response metrics to predict survival in oncology clinical trials. *Clinical Pharmacology and Therapeutics*, **2014**, 95, 386-93	6.1	42
151	Expanding public-private collaborations to enhance cancer drug development: a report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century". **2014**, 19, 1179-85		4
150	Quantifying the probability of clinical trial success from scientific articles. **2014**, 19, 1514-7		2
149	Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. **2014**, 91, 135-43		129
148	Compound Attrition at the Preclinical Phase. **2015**, 46-82		
147	Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. **2015**, 3, 27		15
146	A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds. *Clinical Pharmacology and Therapeutics*, **2015**, 98, 506-13	6.1	17
145	Hepatocyte-Based Metabolism, DrugDrug Interaction, and Toxicity Assays in Drug Discovery and Drug Development to Minimize Attrition. **2015**, 1-15		
144	Statistical Methods for Establishing Personalized Treatment Rules in Oncology. **2015**, 2015, 670691		11
143	Funding Translational Medicine via Public Markets: The Business Development Company. **2015**,		
142	Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy. **2015**, 24 Suppl 2, S84-7		4
141	Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. **2015**, 33, 36-41		12
140	Digital microfluidics for automated hanging drop cell spheroid culture. **2015**, 20, 283-95		59
139	The DIONESUS algorithm provides scalable and accurate reconstruction of dynamic phosphoproteomic networks to reveal new drug targets. **2015**, 7, 776-91		10
138	Toward effective software solutions for big biology. **2015**, 33, 686-7		25
137	Will clinical trial data disclosure reduce incentives to develop new uses of drugs?. **2015**, 33, 685-6		3

136	The erosion of research integrity: the need for culture change. **2015**, 16, 752-4		6
135	Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it. **2015**, 121, 1529-30		14
134	Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today. **2015**, 2015, 29-31		12
133	High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. **2015**, 21, 1318-25		752
132	Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. **2015**, 23, 69-78		146
131	Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety. **2016**, 232, 235-60		21
130	Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report. **2015**, 16, 1-27		85
129	An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. **2016**, 39, 77-86		86
128	Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review. *Oncotarget*, **2016**, 7, 66212-66225	3.3	40
127	Creating a Learning Health Care System in Oncology. **2016**, 3-21		2
126	Systems Pharmacology and Pharmacodynamics. **2016**,		3
125	Using Systems Pharmacology to Advance Oncology Drug Development. **2016**, 421-463		1
124	New Approaches to Drug Discovery. **2016**,		4
123	Systematic characterization of gastrointestinal clinical trials. **2016**, 48, 480-488		1
122	Advancements in Modeling Colorectal Cancer in Rodents. **2016**, 12, 274-280		
121	Failed PET Application Attempts in the Past, Can We Avoid Them in the Future?. **2016**, 18, 797-802		4
120	Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. **2016**, 44, D1069-74		193
119	Innovation in the pharmaceutical industry: New estimates of R&D costs. **2016**, 47, 20-33		1486

118	REGULATION OF HUMAN PHARMACEUTICAL SAFETY. **2017**, 13-58	1
117	Patient-derived xenografts as in vivo models for research in urological malignancies. **2017**, 14, 267-283	49
116	Choosing wisely - Preclinical test models in the era of precision medicine. **2017**, 55, 36-45	28
115	From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers. **2017**, 56, 6712-6733	61
114	Von der Zusammensetzung zur Heilung: ein systemtechnischer Ansatz zur Entwicklung von Trägern für Tumortherapeutika. **2017**, 129, 6814-6837	8
113	Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. **2017**, 7, 12622	16
112	Three-dimensional tumor cell growth stimulates autophagic flux and recapitulates chemotherapy resistance. **2017**, 8, e3013	29
111	Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. **2017**, 8, 435	54
110	Metabolic Profiling of healthy and cancerous tissues in 2D and 3D. **2017**, 7, 15285	50
109	First-Generation Tumor Xenografts: A Link Between Patient-Derived Xenograft Models and Clinical Disease. **2017**, 155-176	1
108	Patient-Derived Xenograft Models of Human Cancer. **2017**,	5
107	Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. **2017**, 28, 34-43	146
106	Embedding real options in scenario planning: A new methodological approach. **2017**, 124, 135-149	24
105	Druggability and Binding Site Interaction Studies of Potential Metabolites Isolated from Marine Sponge Aurora globostellata against Human Epidermal Growth Factor Receptor-2. **2017**, 13, 261-268	2
104	Drug discovery: Chaos can be your friend or your enemy. **2017**, 183-279	1
103	Optimal Financing for R&D-Intensive Firms. **2017**,	3
102	Sharing R&D Risk in Healthcare via FDA Hedges. **2017**,	
101	Predicting human clinical trial responses in mice. **2018**, 5, e1162895	1

100	Controlled multi-arm platform design using predictive probability. **2018**, 27, 65-78		46
99	Therapeutic peptides: Historical perspectives, current development trends, and future directions. **2018**, 26, 2700-2707		814
98	Definitions and statistical properties of master protocols for personalized medicine in oncology. **2018**, 28, 217-228		21
97	The Generation and Application of Patient-Derived Xenograft Model for Cancer Research. **2018**, 50, 1-10		135
96	Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine. *Oncology Letters*, **2019**, 17, 3-10	2.6	37
95	Refining Early Antitumoral Drug Development. **2018**, 39, 922-925		11
94	Strategic decision-making in the pharmaceutical industry: A unified decision-making framework. **2018**, 119, 171-189		6
93	How a drug developer thinks about a new ophthalmic product. **2018**, 16, 390-392		1
92	The Importance of Economic Trade-offs in Cancer Drug Pricing. **2018**, 93, 976-979		2
91	Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. **2018**, 40, 635-646		18
90	Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. **2018**, 52, 220-229		62
89	Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. **2018**, 19,		380
88	Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. **2018**, 227, 158-167		7
87	Personalized Cancer Models for Target Discovery and Precision Medicine. **2018**, 4, 634-642		34
86	Quality of Reporting in Oncology Randomized Controlled Trials: From 2011 to 2015. **2018**, 25, 1073274818781309		
85	Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. **2019**, 8,		80
84	Xenograft and organoid model systems in cancer research. **2019**, 38, e101654		137
83	Japan oncology market overview: Current and future perspectives. **2019**, 15, 104-114		1

82	Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. **2019**, 6, 1900849		25
81	An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids. **2019**, 8,		18
80	How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. **2019**, 22, 777-784		7
79	Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications. **2019**, 24, 457-476		6
78	DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models. **2019**, 17, 39		4
77	Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell. **2019**, 115, 949-959		24
76	Clinical Implementation of Precision Medicine in Gastric Cancer. **2019**, 19, 235-253		6
75	. **2019**,		1
74	Medicines discovery for auditory disorders: Challenges for industry. **2019**, 146, 3652		8
73	The Impact of Early-Phase Trial Design in the Drug Development Process. **2019**, 25, 819-827		24
72	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. **2019**, 3, 385-408		11
71	Empowering phase II clinical trials to reduce phase III failures. **2020**, 19, 178-186		9
70	FDA review times for new drugs in ophthalmology. **2020**, 18, 963-966		2
69	Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine. **2020**, 10,		18
68	Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL. **2020**, 403, 115139		8
67	Computational and Methodological Statistics and Biostatistics. *Emerging Topics in Statistics and Biostatistics*, **2020**,	0.2	
66	Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer. *Frontiers in Oncology*, **2020**, 10, 587377	5.3	0
65	Measurement and models accounting for cell death capture hidden variation in compound response. **2020**, 11, 255		2

64	Advanced drug delivery 2020 and beyond: Perspectives on the future. **2020**, 158, 4-16		34
63	Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. **2020**, 3, 310		11
62	Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies. **2020**, 20, 639-646		2
61	Finding New Drugs for Infectious Diseases: Development Times and Success Rates. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 305-307	6.1	0
60	Choosing The Right Animal Model for Renal Cancer Research. **2020**, 13, 100745		19
59	Medicinal inorganic chemistry: New perspectives and targets for the periodic table. **2020**, 75, 57-86		7
58	Modeling colorectal cancers using multidimensional organoids. **2021**, 151, 345-383		1
57	Quantitative Drug Target Imaging Using Paired-Agent Principles. **2021**, 275-304		
56	Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers. **2021**, 49, 1943-1972		0
55	Differences in the Central Energy Metabolism of Cancer Cells between Conventional 2D and Novel 3D Culture Systems. **2021**, 22,		3
54	Gene expression profiles of liver cancer cell lines reveal two hepatocyte-like and fibroblast-like clusters. *PLoS ONE*, **2021**, 16, e0245939	3.7	2
53	Bioinformatic Approaches to Validation and Functional Analysis of 3D Lung Cancer Models. *Cancers*, **2021**, 13,	6.6	2
52	Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties. *Oncology Letters*, **2021**, 21, 385	2.6	
51	Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer. *BMC Genomics*, **2021**, 22, 214	4.5	7
50	Construction of patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy. *Oncology Letters*, **2021**, 21, 406	2.6	3
49	Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success. *Journal of Parkinsonıs Disease*, **2021**, 11, 421-429	5.3	4
48	Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask. *American Journal of Roentgenology*, **2021**, 216, 1099-1111	5.4	1
47	Approval success rates of drug candidates based on target, action, modality, application, and their combinations. *Clinical and Translational Science*, **2021**, 14, 1113-1122	4.9	3

46	Deep Learning Enables Individual Xenograft Cell Classification in Histological Images by Analysis of Contextual Features. *Journal of Mammary Gland Biology and Neoplasia*, **2021**, 26, 101-112	2.4	1
45	Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 178	12.8	10
44	A Personalized Therapeutics Approach Using an Reveals Optimal Chemo- and Targeted Therapy Combinations for Colorectal Cancer. *Frontiers in Oncology*, **2021**, 11, 692592	5.3	1
43	Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 701429	5.7	3
42	Establishment and Characterization of Feline Mammary Tumor Patient-Derived Xenograft Model. *Animals*, **2021**, 11,	3.1	1
41	The Role of Natural Products as Sources of Therapeutic Agents for Innovative Drug Discovery. **2021** ,		3
40	Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials. *Emerging Topics in Statistics and Biostatistics*, **2020**, 395-426	0.2	1
39	Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio.		1
38	Virotherapy: cancer gene therapy at last?. *F1000Research*, **2016**, 5,	3.6	11
37	Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging. *PLoS ONE*, **2016**, 11, e0160282	3.7	5
36	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. *Oncotarget*, **2018**, 9, 18540-18547	3.3	9
35	Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX). *PeerJ*, **2019**, 7, e6586	3.1	3
34	Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies. *Pharmacological Reviews*, **2021**, 73, 1-32	22.5	2
33	The Cell-Isolation Capsules with Rod-Like Channels Ensure the Survival and Response of Cancer Cells to Their Microenvironment. *Advanced Healthcare Materials*, **2021**, 11, e2101723	10.1	0
32	Nanolipoprotein-Mediated Her2 Protein Transfection Induces Malignant Transformation in Human Breast Acinar Cultures. *ACS Omega*, **2021**, 6, 29416-29423	3.9	0
31	Industry. **2015**, 231-245		
30	Clinical Testing of a New Drug. *Springer Series in Pharmaceutical Statistics*, **2017**, 1-18	1	
29	Risk Assessment Models of the Companies Implementing R&D Projects. *Finance: Theory and Practice*, **2019**, 23, 133-146	0.9	2

28	Biomarkers from Bench to Bedside and Back Back-Translation of Clinical Studies to Preclinical Models. **2020**, 307-331		
27	Nanolipoprotein mediated Her2 protein transfection induces malignant transformation in human breast acinar cultures.		
26	Portfolio and project planning and management in the drug discovery, evaluation, development, and regulatory review process. **2022**, 537-562		
25	In silico Drosophila Patient Model Reveals Optimal Combinatorial Therapies for Colorectal Cancer.		
24	Simulation model for productivity, risk and GDP impact forecasting of the COVID-19 portfolio vaccines.		
23	Clinical Testing of a New Drug. *Springer Series in Pharmaceutical Statistics*, **2021**, 1-21	1	
22	Sharing R&D Risk in Healthcare via FDA Hedges. *Review of Corporate Finance Studies*,	11.3	0
21	Factors associated with successful phase III trials for solid tumors: A systematic review. *Contemporary Clinical Trials Communications*, **2021**, 24, 100855	1.8	
20	Enterprise Optimization in Pharmaceutical Industry. **2021**,		0
19	Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research.. *Cancers*, **2021**, 13,	6.6	2
18	Table_1.docx. **2020**,		
17	Patient-Derived Xenograft: A More Standard Avatar Model in Preclinical Studies of Gastric Cancer. *Frontiers in Oncology*, 12,	5.3	0
16	Eventual success rate and predictors of success for oncology drugs tested in phase I trials. *International Journal of Cancer*,	7.5	0
15	Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization. *Cancers*, **2022**, 14, 2969	6.6	0
14	Recent advances in the development of transplanted colorectal cancer mouse models. *Translational Research*, **2022**,	11	
13	Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies. 13,		1
12	Patient-derived cancer models: Valuable platforms for anticancer drug testing. 12,		
11	The potential of a data centred approach & knowledge graph data representation in chemical safety and drug design. **2022**, 20, 4837-4849		0

10	Therapeutic peptides: historical perspectives and current development trends. **2022**, 3-33	0
9	Harnessing preclinical models for the interrogation of ovarian cancer. **2022**, 41,	0
8	Statistical Innovations in Cancer Research. 1-15	0
7	Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance. **2022**, 22,	0
6	Cancer organoid applications to investigate chemotherapy resistance. 9,	0
5	REGULATION OF HUMAN PHARMACEUTICAL SAFETY: ROUTES TO HUMAN USE AND MARKET. **2023**, 19-66	0
4	Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer. **2023**, 23,	0
3	Experimental mouse models for translational human cancer research. 14,	0
2	Drug discovery: Chaos can be your friend or your enemy. **2023**, 417-511	0
1	Application status and future prospects of the PDX model in lung cancer. 13,	0